New Blood Glucose Meters, Contour® And Breeze®2, Now Available In Pharmacies Nationwide, USA

Main Category: Diabetes
Also Included In: Medical Devices / Diagnostics
Article Date: 01 Mar 2007 - 8:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member of the Bayer Group (NYSE: BAY), announced today the availability of the latest advances in their line of blood glucose meters: the new CONTOUR® and BREEZE®2 meters. As an innovator of meters with No Coding™ technology, Bayer's new meters now offer shorter testing times and easier functionality.

Unlike most meters that need to be manually coded to assure accurate results, CONTOUR and BREEZE2 continue the innovation of previous Bayer meters by automatically setting the correct code any time a Bayer test strip is inserted - so there is less chance for error and fewer steps.

With the new CONTOUR and BREEZE2 blood glucose meters, people with diabetes can now obtain accurate blood glucose test results in just five seconds. The new meters also offer improved test memory to support better diabetes management.

BREEZE2 requires a small blood sample (1µL) size and includes a 10-test disc system, allowing users to test 10 times without handling individual strips, and has received the Ease-of-Use Commendation from the Arthritis Foundation. The new CONTOUR offers automatic features including No Coding™ technology and hematocrit correction, a faster test time, small (0.6 µL) blood sample requirement, meal markers and test reminder alarm.

The new CONTOUR and BREEZE2 blood glucose meters are now available at pharmacies nationwide, or by calling Bayer's free Customer Service Help Line at 1-800-348-8100.

Bayer HealthCare, Diabetes Care

Bayer HealthCare, Diabetes Care is a worldwide leader in diabetes, supporting customers in 100 countries. Since the introduction of CLINITEST® reagent tablets in 1941, Bayer has led the way in diabetes care product innovation. The company changed the face of diabetes care in 1969 when it introduced the first portable blood glucose meter and test strips. Bayer HealthCare further innovated diabetes management by being the first company to introduce a suite of blood glucose monitors with No Coding™ technology. The BREEZE® and CONTOUR® blood glucose monitoring systems offer people with diabetes an unparalleled choice in diabetes management systems. The Arthritis Foundation in the United States and the Arthritis Society of Canada each granted Ease-of Use Commendation to the BREEZE meter, representing the first time a blood glucose meter has been recognized as easy to use for arthritis sufferers.

In July 2006, Bayer Diabetes Care acquired Metrika Inc., maker and manufacturer of A1CNow+®, a meter-based diabetes monitoring system for measurement of HbA1c (glycated hemoglobin) an important indicator of long term blood sugar control.

Bayer HealthCare, Diabetes Care global headquarters is located in Tarrytown, New York, in the United States and operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group.

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

Bayer Diabetes Care
555 White Plains Road
Tarrytown, NY 10591USA
http://www.bayercarediabetes.com

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.